Skip to main content

Explore by
treatment area

Restylane® treatment areas
Actual patient. Individual results may vary.

Explore by treatment area

Cheeks

Create sharper cheek definition or restore natural shape with Restylane Lyft1 and Restylane Contour.2
Learn more

Explore by product

Actual patients. Individual results may vary.
*≥79% of patients (clinical trial subjects) were satisfied with looking less tired through 18 months with optimal treatment.
In a phase IV clinical study, 59 subjects were treated with Restylane Kysse in the lips (n=19) or Restylane Kysse in the lips
in combination with either Restylane Refyne (n=21) or Restylane Defyne (n=37) in the nasolabial folds or marionette lines.
Assessed by an independent photographic reviewer (IPR).

Explore other Galderma Aesthetics treatments

There’s more to love from the Galderma Aesthetics portfolio—and more opportunities to get rewarded with ASPIRE.

@RestylaneUSA

Actual patients. Individual results may vary.
References
  1. Restylane Lyft. Instructions for Use. Galderma Laboratories, L.P., 2023.
  2. Restylane Contour. Instructions for Use. Galderma Laboratories, L.P., 2023.
  3. Restylane Defyne. Instructions for Use. Galderma Laboratories, L.P., 2023.
  4. Restylane Refyne. Instructions for Use. Galderma Laboratories, L.P., 2023.
  5. Restylane. Instructions for Use. Galderma Laboratories, L.P., 2023.
  6. Restylane Kysse. Instructions for Use. Galderma Laboratories, L.P., 2023.
  7. Restylane Silk. Instructions for Use. Galderma Laboratories, L.P., 2023.
  8. Restylane Eyelight. Instructions for Use. Galderma Laboratories, L.P., 2023.
  9. Nikolis A, Berros P, Enright KM, Cordoba M, Nguyen Q. A randomized, crossover-controlled evaluator-blinded trial evaluating cannula- vs needle-assisted hyaluronic acid injections for infraorbital deformities. Aesthet Surg J. 2022;42(3):285-297.
  10. Nikolis A, Chesnut C, Biesman B, et al. Expert recommendations on the use of hyaluronic acid filler for tear trough rejuvenation. J Drugs Dermatol. 2022;21(4):387-392.
Important Safety Information

The Restylane family of products are indicated for patients over the age of 21, and includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine, Restylane® Silk, Restylane® Kysse, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, and Restylane® Eyelight.

Approved Uses

Restylane® and Restylane-L® are for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane® and Restylane-L® are also indicated for injection into the lips.

Restylane® Lyft with Lidocaine is for deep implantation into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and for cheek augmentation and for the correction of age-related midface contour deficiencies. Restylane® Lyft with Lidocaine is also indicated for injection into the dorsal hand to correct volume loss.

Restylane® Silk is for lip augmentation and for correction of perioral wrinkles.

Restylane® Kysse is for lip augmentation and for correction of upper perioral wrinkles.

Restylane® Refyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

Restylane® Defyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds. Restylane® Defyne is also indicated for injection into the mid-to-deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion.

Restylane® Contour is for cheek augmentation and for the correction of midface contour deficiencies.

Restylane® Eyelight is for the improvement of infraorbital hollowing.

Do not use if you have severe allergies with a history of severe reactions (anaphylaxis), are allergic to lidocaine or gram-positive bacterial proteins used to make hyaluronic acid, prone to bleeding, or have a bleeding disorder. The safety of use while pregnant or breastfeeding has not been studied. Tell your doctor if you have a history of scarring or pigmentation disorders as these side effects can occur with hyaluronic acid fillers. Tell your doctor if you are planning other cosmetic treatments (i.e., lasers and chemical peels) as there is a possible risk of inflammation at the injection site.

Tell your doctor if you’re taking medications that lower your body’s immune response or affect bleeding, such as aspirin or warfarin, as these medications may increase the risk of bruising or bleeding at the gel injection site. Using these products on gel injection sites with skin sores, pimples, rashes, hives, cysts, or infections should be postponed until healing is complete.

The most common side effects are swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function. Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers, and cases have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site. The risk of unintentional injection into a blood vessel is small but can occur and could result in serious complications, which may be permanent including, vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. As with all skin injection procedures, there is a risk of infection.

To report a side effect with any Restylane® product, please call Galderma Laboratories, L.P. at 1-855-425-8722.

To learn more about serious but rare side effects and full Important Safety Information, visit www.RestylaneUSA.com.

US-RES-2300327